Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.
GSK reported a robust performance for 2024 with a total sales increase of 7% at constant exchange rates, driven by significant growth in specialty medicines despite a decline in vaccine sales. The company faced a notable decline in total operating profit and EPS primarily due to a substantial charge related to Zantac litigation. However, GSK’s specialty medicines portfolio showed strong momentum, bolstered by advancements in its pipeline and strategic acquisitions. Looking ahead, GSK anticipates growth in turnover, core operating profit, and EPS for 2025, supported by its R&D investments and a planned share buyback program. The company has also raised its 2031 sales outlook, underscoring its strategic focus on long-term growth and shareholder returns.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company operating in the pharmaceutical industry, focusing primarily on the development and production of specialty medicines, vaccines, and general pharmaceuticals. The company has a strong market presence in areas such as respiratory, immunology, oncology, and HIV treatment.
YTD Price Performance: 2.49%
Average Trading Volume: 8,065,132
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £57.08B
Learn more about GSK stock on TipRanks’ Stock Analysis page.
